Abstract:Previously, we have demonstrated that endomorphins (EMs) analogs with C-terminal hydrazide modification retained the μ-opioid receptor affinity and selectivity, and exhibited potent antinociception after intracerebroventricular (i.c.v.) administration. In the present study, we extended our studies to evaluate the antinociceptive profiles of EMs and their analogs EM-1-NHNH2, EM-2-NHNH2 given spinally in the radiant heat paw withdrawal test. Following intrathecal (i.t.) administration, EM-1, EM-2, EM-1-NHNH2 and EM-2-NHNH2 dose-dependently increased the latency for paw withdrawal response. EM-1-NHNH2 displayed the highest antinociceptive effects, with the ED50 values being 1.63 nmol, more potent than the parent EM-1 (1.96 nmol), but with no significant difference. By contrast, the analgesic activities of EM-2 and its analog EM-2-NHNH2 were almost equivalent (P>0.05). Naloxone and β-funaltrexamine (β-FNA) almost completely attenuated the antinociceptive effects of EMs and their analogs EM-1-NHNH2, EM-2-NHNH2 (10 nmol, i.t.), indicating the involvement of μ-opioid receptors. Notably, the antinociception of EM-1 was not significantly antagonized by naloxonazine, a selective μ1-opioid receptor antagonist, but partially reversed the effects of EM-2, suggesting that EM-1 and EM-2 may produce antinociception through distinct μ1- and μ2-opioid receptor subtypes. Moreover, naloxonazine didn't significantly block the antinociceptive effects of EM-1-NHNH2 and EM-2-NHNH2, and nor-BNI, the κ-opioid receptor antagonist, attenuated the analgesic effects of EM-2, but not EM-1, EM-1-NHNH2 or EM-2-NHNH2. These results indicated that C-terminal amide to hydrazide conversion changed the antinociceptive opioid mechanisms of EM-2 but not EM-1 at the spinal level. Herein, the acute antinociceptive tolerance were further determined and compared. EM-1-NHNH2 and EM-2-NHNH2 shifted the dose-response curve rightward by only 2.8 and 1.5-fold as determined by tolerance ratio, whereas EM-1 and EM-2 by 3.4 and 4.6-fold, respectively, indicating substantially reduced antinociceptive tolerance. The present study demonstrated that C-terminal hydrazide modification changes the spinal antinociceptive profiles of EMs.

Synthesis and Antinociceptive Effects of Endomorphin-1 Analogs with C-terminal Linked by Oligoarginine

Novel endomorphin-1 analogs with C-terminal oligoarginine-conjugation display systemic antinociceptive activity with less gastrointestinal side effects.

Endomorphin-1 Analogs with Oligoarginine-Conjugation at C-terminus Produce Potent Antinociception with Reduced Opioid Tolerance in Paw Withdrawal Test.

Endomorphin-2 Analogs with C-terminal Esterification Produce Potent Systemic Antinociception with Reduced Tolerance and Gastrointestinal Side Effects

Design, Synthesis, and Evaluation of New Endomorphin Analogs with Enhanced Central Antinociception after Peripheral Administration.

Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects

In Vitro and in Vivo Characterization of Opioid Activities of C-terminal Esterified Endomorphin-2 Analogs

Endomorphin-2 Analogs with C-terminal Esterification Display Potent Antinociceptive Effects in the Formalin Pain Test in Mice.

Design, Synthesis, and Biological Activity of New Endomorphin Analogs with Multi-Site Modifications

The spinal anti-allodynic effects of endomorphin analogs with C-terminal hydrazide modification in neuropathic pain model

C-terminal Hydrazide Modification Changes the Spinal Antinociceptive Profiles of Endomorphins in Mice.

Novel endomorphin analogs CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favorable side effect profile at the spinal level

Utilization of Combined Chemical Modifications to Enhance the Blood-Brain Barrier Permeability and Pharmacological Activity of Endomorphin-1

Differential Antinociceptive Effects of Intrathecal Administration of C‐terminal Esterified Endomorphin‐2 Analogues in Mice

Characterization of Opioid Activities of Endomorphin Analogs with C-Terminal Amide to Hydrazide Conversion

Novel Endomorphin Analogues CEMR-1 and CEMR-2 Produce Potent and Long-Lasting Antinociception with a Favourable Side Effect Profile at the Spinal Level

Structure-Constrained Endomorphin Analogs Display Differential Antinociceptive Mechanisms in Mice after Spinal Administration

Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics

In vitro and in vivo characterization of opioid activities of endomorphins analogs with novel constrained C-terminus: evidence for the important role of proper spatial disposition of the third aromatic ring.

Contribution of the μ opioid receptor and enkephalin to the antinociceptive actions of endomorphin-1 analogs with unnatural amino acid modifications in the spinal cord

Structure–activity Study of Endomorphin-2 Analogs with C-terminal Modifications by NMR Spectroscopy and Molecular Modeling